Development and Implementation of a High-Throughput High-Content Screening Assay to Identify Inhibitors of Androgen Receptor Nuclear Localization in Castration-Resistant Prostate Cancer Cells

Patients with castration-resistant prostate cancer (CRPC) can be treated with abiraterone, a potent inhibitor of androgen synthesis, or enzalutamide, a second-generation androgen receptor (AR) antagonist, both targeting AR signaling. However, most patients relapse after several months of therapy and...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Assay Drug Dev Technol
Autors principals: Johnston, Paul A., Nguyen, Minh M., Dar, Javid A., Ai, Junkui, Wang, Yujuan, Masoodi, Khalid Z., Shun, Tongying, Shinde, Sunita, Camarco, Daniel P., Hua, Yun, Huryn, Donna M., Wilson, Gabriela Mustata, Lazo, John S., Nelson, Joel B., Wipf, Peter, Wang, Zhou
Format: Artigo
Idioma:Inglês
Publicat: Mary Ann Liebert, Inc. 2016
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4876501/
https://ncbi.nlm.nih.gov/pubmed/27187604
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/adt.2016.716
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars